Stakeholders are taking issue with the US Food and Drug Administration’s (FDA) draft guidance on conducting bioresearch monitoring (BIMO) inspections. They are particularly concerned about protecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results